![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SJ Weber, DL Greene, SD Sharma, HI Yamamura, TH Kramer, TF Burks, VJ Hruby, LB Hersh and TP Davis
Department of Pharmacology, University of Arizona, Tucson.
To improve pharmacological characteristics of the delta-selective, cyclic peptide [D-Pen2, D-Pen5]enkephalin (DPDPE), modification by halogenation at the Phe4 residue was undertaken. The present study was to determine the extent [3H]DPDPE, [3H][p-Cl-Phe4]DPDPE and [p- 125IPhe4]DPDPE crosses the blood-brain barrier, elicits analgesia and to characterize selective organ distribution and stability after i.v. administration. A significantly greater percentage of total [3H][p-Cl- Phe4]DPDPE reached the brain after 10, 20 and 40 min as compared to [3H]DPDPE and both peptides were significantly displaced by pretreatment with naloxone or naltrindole. The amount of [3H]DPDPE detected in the brain was greater than that of [p-125IPhe4]DPDPE. Distribution results revealed large amounts of the administered peptides were sequestered rapidly in the gall bladder and secreted into the small intestine. Hot-plate antinociception tests 5 min after i.v. administration (30 and 60 mg/kg) revealed [p-Cl-Phe4]DPDPE to elicit a much greater analgesic effect as compared to DPDPE or [p- 125IPhe4]DPDPE. These results provide evidence that [p-Cl-Phe4]DPDPE has a greater apparent distribution to the brain and has a greater effect on the antinociception threshold as tested on the hot-plate than DPDPE or [p-125IPhe4]DPDPE. Stability of unlabeled and tritiated DPDPE and [p-Cl-Phe4]DPDPE was determined both in vitro and in vivo; both unlabeled and tritiated DPDPE and [p-Cl-Phe4]DPDPE remain intact.
This article has been cited by other articles:
|
|
 |
|
  H.-M. Liu, X.-F. Liu, J.-L. Yao, C.-L. Wang, Y. Yu, and R. Wang Utilization of Combined Chemical Modifications to Enhance the Blood-Brain Barrier Permeability and Pharmacological Activity of Endomorphin-1 J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Hoffmaster, M. J. Zamek-Gliszczynski, G. M. Pollack, and K. L. R. Brouwer MULTIPLE TRANSPORT SYSTEMS MEDIATE THE HEPATIC UPTAKE AND BILIARY EXCRETION OF THE METABOLICALLY STABLE OPIOID PEPTIDE [D-PENICILLAMINE2,5]ENKEPHALIN Drug Metab. Dispos., February 1, 2005; 33(2): 287 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gao, B. Hagenbuch, G. A. Kullak-Ublick, D. Benke, A. Aguzzi, and P. J. Meier Organic Anion-Transporting Polypeptides Mediate Transport of Opioid Peptides across Blood-Brain Barrier J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 73 - 79. [Abstract] [Full Text]
|
|
|
|
|
|
C. Chen and G. M. Pollack Altered Disposition and Antinociception of [D-Penicillamine2,5] Enkephalin in mdr1a-Gene-Deficient Mice J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 545 - 552. [Abstract] [Full Text]
|
|
|
|
|
|
C. Chen and G. M. Pollack Blood-Brain Disposition and Antinociceptive Effects of [D-Penicillamine2,5]enkephalin in the Mouse J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1151 - 1159. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Thomas, T. J. Abbruscato, V. J. Hruby, and T. P. Davis The Entry of [D-Penicillamine2,5]Enkephalin into the Central Nervous System: Saturation Kinetics and Specificity J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1235 - 1240. [Abstract] [Full Text]
|
|
|
|
|
|
T. J. Abbruscato, S. A. Thomas, V. J. Hruby, and T. P. Davis Blood-Brain Barrier Permeability and Bioavailability of a Highly Potent and µ-Selective Opioid Receptor Antagonist, CTAP: Comparison with Morphine J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 402 - 409. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
